Active, not recruitingPHASE1, PHASE2NCT06392126

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

Studying Juvenile amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
n-Lorem Foundation
Principal Investigator
Björn E. Oskarsson, M.D.
Mayo Clinic
Intervention
nL-CHCHD-001(drug)
Enrollment
1 enrolled
Eligibility
48 years · MALE
Timeline
20242026

Study locations (1)

Collaborators

Mayo Clinic

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06392126 on ClinicalTrials.gov

Other trials for Juvenile amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Juvenile amyotrophic lateral sclerosis

← Back to all trials